Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

The coagulopathy of cancer

The coagulopathy of cancer REVIEW URRENT PINION Anna Falanga, Laura Russo, and Viola Milesi Purpose of review To provide an updated overview of the complex coagulopathy associated with malignancy, together with the advances in our knowledge of the interactions of cancer with the hemostatic system. Also, to offer an update of the recent progresses in the risk assessment, prevention, and treatment of thrombohemorrhagic complications in cancer patients. Recent findings Mechanisms underlying the hemostatic derangement caused by cancer include many prothrombotic properties of tumor tissues. Of extreme interest are the most recent findings that the regulation of tumor cell hemostatic protein expression is driven by oncogenes, the tumor-derived tissue factor-positive microparticles are an important player in thrombosis, and the changes in the tumor microenvironment in the presence of tissue factor affect ‘dormant’ cells to shift to a malignant phenotype. On the clinical side, risk assessment models, based on clinical and biological risk factors, are becoming very attractive to identify categories of cancer patients at different thrombotic risk. Unsuspected pulmonary embolism, incidentally discovered, is also opening an intensive area of research. Finally, new updates of the guidelines to help clinicians in the management of venous thromboembolism in cancer patient have been recently released. Summary The http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in Hematology Wolters Kluwer Health

The coagulopathy of cancer

Milesi, Viola
Current Opinion in Hematology , Volume 21 (5) – Sep 1, 2014
Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/the-coagulopathy-of-cancer-Zc3UZVJkS6

References (51)

Copyright
© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins
ISSN
1065-6251
eISSN
1531-7048
DOI
10.1097/MOH.0000000000000072
pmid
25054907
Publisher site
See Article on Publisher Site

Abstract

REVIEW URRENT PINION Anna Falanga, Laura Russo, and Viola Milesi Purpose of review To provide an updated overview of the complex coagulopathy associated with malignancy, together with the advances in our knowledge of the interactions of cancer with the hemostatic system. Also, to offer an update of the recent progresses in the risk assessment, prevention, and treatment of thrombohemorrhagic complications in cancer patients. Recent findings Mechanisms underlying the hemostatic derangement caused by cancer include many prothrombotic properties of tumor tissues. Of extreme interest are the most recent findings that the regulation of tumor cell hemostatic protein expression is driven by oncogenes, the tumor-derived tissue factor-positive microparticles are an important player in thrombosis, and the changes in the tumor microenvironment in the presence of tissue factor affect ‘dormant’ cells to shift to a malignant phenotype. On the clinical side, risk assessment models, based on clinical and biological risk factors, are becoming very attractive to identify categories of cancer patients at different thrombotic risk. Unsuspected pulmonary embolism, incidentally discovered, is also opening an intensive area of research. Finally, new updates of the guidelines to help clinicians in the management of venous thromboembolism in cancer patient have been recently released. Summary The

Journal

Current Opinion in Hematology – Wolters Kluwer Health

Published: Sep 1, 2014

There are no references for this article.